Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
Background Immune checkpoint (IC) blockades (ICBs) significantly improve patients’ clinical outcomes with solid tumors. Because the objective response rate of single-agent ICB is limited, it is meaningful to explore the combination of ICs for immunotherapy.Methods RNA sequencing data of 95 newly dia...
Saved in:
| Main Authors: | Qing Li, Yong Wu, Ting Liu, Peipei Wang, Yueyun Chen, Qingqin Long, Jiangfang Tian, Zhenyu Ding |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e002836.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
by: Paul Nghiem, et al.
Published: (2020-10-01) -
Three Survival-Related Genes of Esophageal Squamous Cell Carcinoma Identified by Weighted Gene Coexpression Network Analysis
by: Di Lu, et al.
Published: (2021-01-01) -
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01) -
LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01) -
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies
by: Astrid Musnier, et al.
Published: (2025-03-01)